phone: +46 (0)42 20 71 10 | e-mail: info@caprascience.com
 Capra Science has invested in increased production capacity of polyclonal antibody generation during 2015. This expansion is a natural advancement to meet up with the steadily increasing demand of antibodies from Capra Science. Antibodies that are produced with high ethical standards.
A therapeutic antibody, adunacumab (BIIB037) from Biogen, has shown to reduce the amyloid plaque in the brain of Alzheimers patients. This is a true brake through in the Alzheimers research field.
“This is the first time an investigational drug for Alzheimer’s disease has demonstrated a statistically significant reduction on amyloid plaque as well as a statistically significant slowing of clinical impairment in patients with prodromal or mild disease,” said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen Idec. “Based on these results, we are advancing the aducanumab clinical program to Phase 3 with plans to initiate enrollment later this year.” See Biogen's press-release here.
Questions? Or struggling with an antibody-related problem? Come to us, the consultation is free of charge.
/Capra Science Antibodies Team info@caprascience.com
These are things we are both happy about and proud of having achieved. The last point really makes us warm at heart since meeting and exceeding our customers expectations is what makes us grow and is of real importantace for us as we continue to move grow. We now look forward to a new year with new interesting projects and new challenges to take on. We would also like to take the opportunity to wish all our customers and collaborators all the best for 2015!
We will still be open for recieving samples during the holidays. However, please make sure to inform us by email with the shipping details (shipper and tracking number), so that we can make sure that the package reaches us with no delays (inform us at info@caprascience.com). The Capra Science team wishes you a Happy Holiday and look forward to the new year.
The study, conducted by Jan Voskuil (CSO of Everest Biotech Ltd), shows that the antibody vendors buy and re-label antibodies from each other, and not from the manufacturers, in order to ramp up the numbers of antibodies on stock. This results in the exact same antibody appearing multi-fold on many catalogues worldwide, often marked with outdated or incorrect QC data.
The issue goes deeper than this though. As it turns out, even buying the exact product as endorsed by scientific publications does not guarantee that you will get the antibody that was successfully used in the publication. This is due to flawed QA procedures taken on by vendors who re-label antibodies bought from other antibody banks without regarding batch-to-batch variation. Judging by the extensive increase of antibodies these banks are offering, this problem will not go away any time soon. More likely it will become an even bigger nuisance as the banks expand their catalogues without buying directly from the manufacturers. Stay tuned to see how custom antibody production at a manufacturer like Capra Science can give you significant advantages in your research, R&D and immunodiagnostics. The Nov2k symposium - which had 2014 Nobel Prize winner Edvard Moser as keynote speaker last year - has invited the founder of Capra Science to deliver a talk on this year's event. The topic of the talk is 'improving animal welfare in antibody production'.
Nov2k is a multidisciplinary, interactive scientific symposium taking place at Novum, on Karolinska Institutet’s campus in Huddinge on the 20th-21st November. |
Capra Science is your Antibody Expert and your No. 1 choice for Antibody Services.
Categories |
RSS Feed